BPC continued its series on affordable medicines, examining the role of federal government policy on pharmaceutical innovation, market competition, and costs.
Educational Series on Affordable Medicines: Impact of Federal Policy on Innovation, Competition, and Costs
The forum was the second in a series examining how private sector decisions and public sector policies impact the prices of drugs and their costs to the health care system.
Chronic diseases are costing American families, businesses, and government at all levels. Prevention is a powerful tool, but achieving national results has been difficult.
While few expect the budget to pass in 2016, policymakers may want to carefully examine some of the budget’s proposed innovations to use in the near future.
Currently, five federal agencies fund multiple programs that provide assistance for the aging such as in-home services, affordable housing and transportation.
Alternatives to fee-for-service have proliferated in recent years as the government, private insurers, and employers seek increased value in the health care system.
The transition away from fee-for-service to more coordinated systems of care will benefit beneficiaries across the Medicare program, and particularly those living with chronic conditions.
There is growing recognition that prevention holds vast potential to improve health, while also reducing national spending on health care.
Americans spend twice as much on health care as citizens of other developed nations, yet we have shorter life expectancies and higher rates of infant mortality and diabetes.